Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer

Two-year disease-free survival from evaluable Phase 2 patients expected by the end of Q1 2028.Strasbourg, France, April 13, 2026, 8:00 a.m. CET – ...

Transgene S.A.: Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer

Two-year disease-free survival from evaluable Phase 2 patients expected by the end of Q1 2028. Strasbourg, France, April 13, 2026, 8:00 a.m. CET - Transgene (Euronext Paris: TNG), a biotech company th ...